Abstract:Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp, encoded by MDR1) play an important role in the absorption and metabolism of tacrolimus. The objective of this study was to evaluate whether or not CYP3A5*1/*3 or MDR1 C3435T polymorphisms are associated with the tacrolimus concentration per dose.Methods: CYP3A5 and MDR1 genotypes were determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis in 118 Chinese renal transplant patients receiving tacrolimus. Whole blood trough tacrolimus concentration was measured by enzyme-linked immunosorbent assay and dose-adjusted concentration (ng/mL per mg/kg/d) was calculated at 1 wk, 1 month, and 3 months after transplantation.Results: The dose-adjusted concentration of CYP3A5*1/*1 and *1/*3 patients was significantly lower than *3/*3 patients (32.8 +/- 17.7 and 41.6 +/- 15.8 vs. 102.3 +/- 51.2 at 1 wk; 33.1 +/- 7.5 and 46.4 +/- 12.9 vs. 103 +/- 47.5 at 1 month; 35.3 +/- 20.9 and 59.0 +/- 20.6 vs. 150 +/- 85.3 at 3 months after transplantation respectively). At 1 wk, 46% of the CYP3A5*1 allele carriers had a tacrolimus concentration lower than 5 ng/mL and 77% lower than 8 ng/mL, whereas 20% of the *3/*3 patients had a concentration higher than 20 ng/mL. There was a mild difference between *1/*1 homozygotes and *1/*3 heterozygotes at 1 and 3 months after transplantation. No difference was found among the MDR1 genotypes.Conclusion: CYP3A5*1/*3 polymorphisms are associated with tacrolimus pharmacokinetics and dose requirements in renal transplant recipients. Pharmacogenetic methods could be employed prospectively to help initial dose selection and to individualize immunosuppressive therapy.

Relationship Between Different CYP3A5*3 Genotypes and Sirolimus Plasma Concentration in Chinese Renal Transplant Recipients

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Relationship between genetic polymorphism of CYP3A5 gene and blood concentration/dose ratio of sirolimus in renal transplant patients

Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.

The population pharmacokinetics of sirolimus and CYP 3 A 5 * 3 polymorphism in Chinese renal transplant patients

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Population Pharmacokinetics of Sirolimus in Chinese Renal Transplantation Patients

Polymorphisms in Thecyp3a5gene Significantly Affect the Pharmacokinetics of Sirolimus after Kidney Transplantation

Genetic Polymorphism of CYP3A in Chinese Renal Transplant Population

Influence of CYP3A5 Genetic Polymorphism on Cyclosporine A Metabolism and Elimination in Chinese Renal Transplant Recipients

Influence of CYP 3A5*3 genetic polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

Influence Of Cyp3a5 And Mdr1 Polymorphisms On Tacrolimus Concentration In The Early Stage After Renal Transplantation

Influence of cytochrome P450 3A family polypeptide 5 genetic polymorphisms on tacrolimus in renal transplant patients

Influence of CYP3A5 and MDR1(ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Recipients

Effect of CYP3A5 polymorphism on the concentration /dose ratio of tacrolimus in liver transplant recipients

Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.

Effects of CYP3A5 * 3 Polymorphisms on Tacrolimus Pharmacokinetic in Renal Transplantation Recipients by PyrosequencingTM

Influence of the MDR1 Haplotype and CYP3A5 Genotypes on Cyclosporine Blood Level in Chinese Renal Transplant Recipients.

CYP3a5 Genetic Polymorphism in Chinese Population With Renal Transplantation: A Meta-Analysis Review

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients